Olpasiran
amgen
[]
 presents the outstanding results of the ocean(a)-dose trial. #aha2022 olpasiran, an sirna, led to a 95% reduction in lp(a) concentrations dosed 75 mg or higher every 12 weeks. 
Cardiovascular Medicine Fellow @BrighamWomens @HarvardMed | Research Fellow @TIMIStudyGroup | Forbes 30 Under 30 | Proud Alum @Caltech